Developing an ADC, AOC, RDC, or bispecific? Schedule a meeting with our experts in stand 6.1B26 during CPHI Frankfurt 2025, 28-30 October, to discover how we can streamline and de-risk your drug development journey.  Our scientific and commercial leadership welcome the opportunity to schedule some time to connect on your project-specific needs and to provide you with an update on our newly expanded global discovery, development, and manufacturing capabilities.

Our attendees include:

• Dr Campbell Bunce, CSO
• Joe Principe, CCO
• Dr Petra Dieterich, SVP & Scientific Leader
• Gavin Murdoch, SVP, Commercial Strategy
• Kimberly Burrell, SVP, Global Marketing
• Jonathan Cruickshank, Head of Business Development, Europe & APAC
• Gildas Lavenant, VP of Business Development
• Roger Bowie, VP of Business Development

From antibodies (mAbs) to recombinant vaccines and bioconjugates- including ADCs, RDCs (radioconjugates), and AOCs (antiboday-oligonucleotide conjugates)- our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone. With over two decades of expertise, 2000+ conjugates developed and 200+ cell lines, we come equipped with the technical know-how and state-of-the-art technologies needed to deliver a simplified and secure supply chain.

We can also provide you with an update on our expanded global capabilities and enhanced platform technology like AbZelectPRO™, our enhanced cell line development solution. AbZelectPRO™ can take you from DNA to RCB in 10 weeks with 10g/L in high-performing titers. If you are ready to achieve more from your cell line and reach IND faster, discover AbZelectPRO™.

We look forward to the discussion!